These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

143 related items for PubMed ID: 6815155

  • 21. [New aminoglycoside antibiotics].
    Dzierzanowska D.
    Pol Tyg Lek; 1977 Sep 19; 32(38):1483-6. PubMed ID: 905200
    [No Abstract] [Full Text] [Related]

  • 22. Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: V. Aminoglycosides.
    Young DC, Zobell JT, Stockmann C, Waters CD, Ampofo K, Sherwin CM, Spigarelli MG.
    Pediatr Pulmonol; 2013 Nov 19; 48(11):1047-61. PubMed ID: 24000183
    [Abstract] [Full Text] [Related]

  • 23. Post-antibiotic effect of colistin, alone and in combination with amikacin, on Pseudomonas aeruginosa strains isolated from cystic fibrosis patients.
    Bozkurt-Güzel C, Gerçeker AA.
    J Antibiot (Tokyo); 2012 Feb 19; 65(2):83-6. PubMed ID: 22126897
    [No Abstract] [Full Text] [Related]

  • 24. Tobramycin, amikacin, sissomicin, and gentamicin resistant Gram-negative rods.
    Drasar FA, Farrell W, Maskell J, Williams JD.
    Br Med J; 1976 Nov 27; 2(6047):1284-7. PubMed ID: 1000196
    [Abstract] [Full Text] [Related]

  • 25. [Comparison of the antibacterial activity of amikacin (BB-K8) with other aminoglycosides against pathogens recently isolated from clinical materials (author's transl) ].
    Kosakai N, Oguri T.
    Jpn J Antibiot; 1975 Aug 27; 28(4):530-7. PubMed ID: 240047
    [Abstract] [Full Text] [Related]

  • 26. [Clinical pharmacology of the most frequently used aminoglucosides: gentamycin, tobramycin and amikacin].
    Cuena Boy R, Azanza Perea JR, Echeverría Echepare LM, Honorato Pérez J.
    Rev Med Univ Navarra; 1983 Dec 27; 27(4):21-7. PubMed ID: 6676898
    [No Abstract] [Full Text] [Related]

  • 27. Inhaled tobramycin (TOBI): a review of its use in the management of Pseudomonas aeruginosa infections in patients with cystic fibrosis.
    Cheer SM, Waugh J, Noble S.
    Drugs; 2003 Dec 27; 63(22):2501-20. PubMed ID: 14609360
    [Abstract] [Full Text] [Related]

  • 28. An Antipersister Strategy for Treatment of Chronic Pseudomonas aeruginosa Infections.
    Koeva M, Gutu AD, Hebert W, Wager JD, Yonker LM, O'Toole GA, Ausubel FM, Moskowitz SM, Joseph-McCarthy D.
    Antimicrob Agents Chemother; 2017 Dec 27; 61(12):. PubMed ID: 28923873
    [Abstract] [Full Text] [Related]

  • 29. Amikacin therapy of exacerbations of Pseudomonas aeruginosa infections in patients with cystic fibrosis.
    Lau WK, Young LS, Osher AB, Dooley RR.
    Pediatrics; 1977 Sep 27; 60(3):372-7. PubMed ID: 408787
    [Abstract] [Full Text] [Related]

  • 30. [Comparative activity of habekacin and 4 other aminoglycosides against gram-negative bacilli. Evolution of resistance].
    Reynaud AE, Coude du Foresto B, Derriennic M, Courtieu AL.
    Pathol Biol (Paris); 1988 May 27; 36(5):435-8. PubMed ID: 3136424
    [Abstract] [Full Text] [Related]

  • 31. Amikacin and netilmicin resistance in Pseudomonas aeruginosa: incidence and transfer.
    Knothe H, Krcméry V.
    Chemotherapy; 1979 May 27; 25(1):23-9. PubMed ID: 105839
    [No Abstract] [Full Text] [Related]

  • 32. Tobramycin and ticarcillin therapy for exacerbations of pulmonary disease in patients with cystic fibrosis.
    Parry MF, Neu HC.
    J Infect Dis; 1976 Aug 27; 134 Suppl():S194-7. PubMed ID: 823276
    [Abstract] [Full Text] [Related]

  • 33. Combined imipenem/cilastatin and tobramycin therapy of multiresistant Pseudomonas aeruginosa in cystic fibrosis.
    Pedersen SS, Pressler T, Jensen T, Rosdahl VT, Bentzon MW, Høiby N, Koch C.
    J Antimicrob Chemother; 1987 Jan 27; 19(1):101-7. PubMed ID: 3104273
    [Abstract] [Full Text] [Related]

  • 34. [Susceptibility of Pseudomonas aeruginosa to aminoglycosides: effect of free calcium and magnesium].
    Christe M, Vaudaux P, Waldvogel FA.
    Schweiz Med Wochenschr; 1982 Feb 13; 112(7):234-41. PubMed ID: 6803358
    [Abstract] [Full Text] [Related]

  • 35. No benefit of longer eradication therapy of Pseudomonas aeruginosa primoinfections in pediatric cystic fibrosis.
    Claude F, Rochat I, Hafen GM.
    BMC Res Notes; 2019 Mar 04; 12(1):115. PubMed ID: 30832714
    [Abstract] [Full Text] [Related]

  • 36. Use of Calgary and Microfluidic BioFlux Systems To Test the Activity of Fosfomycin and Tobramycin Alone and in Combination against Cystic Fibrosis Pseudomonas aeruginosa Biofilms.
    Díez-Aguilar M, Morosini MI, Köksal E, Oliver A, Ekkelenkamp M, Cantón R.
    Antimicrob Agents Chemother; 2018 Jan 04; 62(1):. PubMed ID: 29084746
    [Abstract] [Full Text] [Related]

  • 37. [Enterobacteria isolated in hospitals. Comparison of the bacteriostatic and bactericidal activity of amikacin, gentamicin and tobramycin].
    Kazmierczak A, Gailliard MC, Pothier P, Siebor E, Portier H.
    Nouv Presse Med; 1979 Oct 31; 8(42):3399-402. PubMed ID: 537884
    [No Abstract] [Full Text] [Related]

  • 38. Routine susceptibility tests with ticarcillin and tobramycin in combination should be more appropriate than with each antibiotic alone in cystic fibrosis Pseudomonas aeruginosa.
    Lapointe JR, Bourget C, Mainville S, Lafleur L, Lagacé J, Montplaisir S.
    J Chemother; 1989 Jul 31; 1(4 Suppl):184-6. PubMed ID: 16312360
    [No Abstract] [Full Text] [Related]

  • 39. Isolation of an amikacin-resistant Escherichia coli strain after tobramycin treatment of previous recurrent episodes of respiratory tract infections caused by Pseudomonas aeruginosa.
    Ruiz J, Bertran S, Sauca G, Julià A, Vila X, Gómez E, Jiménez de Anta MT, Vila J.
    Clin Microbiol Infect; 2005 Jan 31; 11(1):71-3. PubMed ID: 15649309
    [Abstract] [Full Text] [Related]

  • 40. Antimicrobial susceptibility of Pseudomonas aeruginosa before and after initiation of inhaled tobramycin in Bulgaria.
    Petrova G, Strateva T, Miteva D, Lazova S, Perenovska P.
    J Infect Dev Ctries; 2016 Nov 24; 10(11):1265-1267. PubMed ID: 27886041
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.